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One of the prominent types of connective tissue cells is fibroblast that synthesizes and maintains 
the extracellular matrix of many animal tissues. Previous studies illustrated that calprotectin 
protein has different cytotoxicity effects on fibroblast cells. Calprotectin is abundant in the 
neutrophil cytosol; it has growth-inhibitory and apoptosis-inducing activities against various 
cell types such as tumor cells. The present study tries to introduce mechanism of growth 
inhibitory effect of calprotectin on human foreskin fibroblast cells (HFFF) and compare to 
etoposide (chemotherapy agent as control). Calprotectin was purified from human neutrophil by 
chromatography methods. HFFF cell lines were used, maintained in RPMI 1640 medium 
supplemented with 10% FCS in a humidified incubator (37 ºC & 5% CO2). The HFFF cells 
were exposed to the different concentrations of calprotectin and etoposide for 24, 48 and 72 
hours. Cell proliferation was assessed by using dimethylthiazol diphenyl tetrazolium bromide 
assay. Flow cytometric analysis was performed to evaluate the cytotoxic mechanism of 
calprotectin on HFFF cells. Our results revealed that calprotectin and etoposide induce growth 
inhibition of HFFF in dose- and time-dependent manners. Sensitivity of HFFF cells to cytotoxic 
effect of human calprotectin was highly remarkable. In addition, growth inhibitory effect of this 
cytotoxic agent mostly was governed through induction of apoptosis in the HFFF cells. Taken 
together, calprotectin not only has more potent anticancer activity in comparison with the 
etoposide, but it also is an apoptosis inducer that acts on the proliferation of normal cells like 
fibroblasts. 
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INTRODUCTION 
    Calprotectin is a heterodimeric protein 
complex with zinc and calcium binding 
capacity. It is predominantly found in 
cytosolic component of neutrophils [1-4]. 
Calprotectin exhibits growth inhibitory and 
apoptosis inducing activity against some 
normal and a broad spectrum of tumor cells 
with different origins; i.e., MM46 mouse 
mammary carcinoma, MH-134 mouse 
hepatoma, EL-4 mouse thymoma, L-929 
mouse fibrosarcoma, B16 mouse melanoma, 
J774.1 mouse macrophage-like cells, 
Ros17/2.8, rat osteosarcoma, MCF-7 human 
mammary adenocarcinoma, MOLT-4 human 
leukemia cells and AGS gastric 
adenocarcinoma cell [1, 2, 5-7]. Several 
reports suggest that cell death inducing 
activity of calprotectin is due to exclusion of 
zinc from target cells [8, 9], and may obey 
single target single hit theory via binding to its 
receptor [1]. However, previous studies 
demonstrate that calprotectin inhibits the 
activity of casein kinase II, which is involved 
in the phosphorylation of several enzymes 
including topoisomerase I and II [10, 11]. 
Etoposide has been clinically used for more 
than two decades and is remained one of the 
most highly prescribed anticancer drugs in the 
world [12]. It is used as an apoptosis inducer 
in a variety of cells including breast, lung, 
prostate and some of gastric cancer cell lines 
[13-15]. It has been reported that etoposide 
also has deleterious effects on normal cells 
[16]. In a previous study cytotoxicity effects of 
calprotectin on two different human fibroblast 
cells were compared. It has been investigated 
that calprotectin has different effect on two 
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different kinds of fibroblast, but its effect on 
melanoma cancer cells compar to the 
fibroblast was further. [17]. A fibroblast is a 
type of cell that synthesizes and maintains the 
extracellular matrix of many animal tissues 
[18]. When a tissue is injured, the fibroblasts 
nearby proliferate, migrate into the wound and 
produce large amounts of collagenous matrix 
which helps to isolate and repair the damaged 
tissue [19]. As mentioned above about 
cytotoxicity effect of calprotectin on 
fibroblast, in this study, apoptotic effects of 
calprotectin on human fibroblast cell were 
evaluated and compared with etoposide. 
 
MATERIALS AND METHODS 
    Dithiothreitol (DTT) and lymphoprep were 
obtained from Merck and Amersham 
Companies, respectively. Fetal calf serum 
(FCS) was obtained from Gibco and Seromed-
Germany. RPMI 1640 medium, penicillin, 
streptomycin, MTT (dimythylthiazol diphenyl 
tetrazolium bromide) were all purchased from 
Sigma Chemical Co. at least of analytical 
grade. In situ cell death detection kit 
(Annexin-V FITC) was purchased from IQ 
products (Netherlands). Flask, tubes and 
culture plates were obtained from Griner- 
Germany. Other chemicals used in this study 
were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA).  All solutions were 
made by deionized double distilled water. 
Cell line.Human fetal foreskin fibroblast 
(HFFF-PI6, NCBI: C-170) was obtained from 
National Cell Bank of Iran, Pasteur Institute of 
Iran. These cells were maintained in RPMI 
1640 medium supplemented with 10% FCS in 
a humidified incubator (37 ºC & 5% CO2).  
  
Calprotectin purification 
 Human neutrophils were prepared from 
leukocyte-rich blood fractions (buffy coat) 
according to the method of previous works 
[20, 21]. Method of purification of human 
calprotectin was described previously [21]. 
Calprotectin was purified from Q sepharose 
and SP sepharose chromatography. The SDS 
page electrophoresis gel confirms protein 
purity.  
 
Incubation of calprotectin and etoposide 
with HFFF cells 
 HFFF cells were cultured in RPMI-1640 
medium supplemented with 10 % heat 
inactivated fetal calf serum (FCS), 2mM 
glutamine, penicillin (100 IU/ml) and 
streptomycin (100 µg/ml) at 37 ºC in an 
incubator containing 5 % CO2. Harvested cells 
were seeded into 96-well plates (1×104 
cell/well) and incubated with the different 
concentrations of calprotectin and etoposide 
(0, 1.025, 2.05, 4.1, 8.2 and 16.4µM) for 24, 
48 and 72 h. For each concentration of drugs, 
six wells of 96-well plates containing 1×104 
HFFF cells were used. In each experiment, six 
HFFF cultured wells with no drug were used 
as negative controls. The cultured medium 
was controlled every day.  
 
Viability Test 
 Relative cell number was measured using 
MTT assay (dimethylthiazol diphenyl 
tetrazolium bromide) [22].  
 The percentage of cytotoxicity was calculated 
according to following formulas: 
 
%Cytotoxicity=100(1-AT/AN)                 (1) 
 
That AT and AN are mean absorbance of 
toxicant-treated cells and mean absorbance of 
negative control cells respectively.  
 
% Viability = 100 - % Cytotoxicity            (2)  
  
LC50 Determination 
 LC50 was determined by probit analysis using 
the pharm. PCS statistical package (Springer-
Verlage, New York).  
 
Flow cytometry analysis 
 For flow cytometry analysis, HFFF cells were 
cultured into 6-well plates at a density of 5 × 
105 cells with and without the cytotoxic 
agents at 18, 36 and 48 h. All floated and 
adherent cells were harvested and centrifuged 
at 200 ×g for 10 min. Cell pellet was washed 
with 1X calcium binding buffer and 
centrifuged at 200 ×g for 10 min. Ten 
microliters of Annexin V/FITC was added to 
100 µl of cell suspension containing 106 cells, 
and incubated at 4°C for 20 minutes. Then, the 
cells were washed again with the calcium 
binding buffer and 10 µl of propidium iodide 
(PI) was added and incubated at 4°C for 10 
min and analysis was performed by a flow 
cytometer (Bio-Rad, USA). FL1 and FL2 
channels were used for detection of 
Annexin/FITC and PI, respectively. 
Concentration of the calprotectin giving 50% 
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cytotoxicity (LC50) (38 µM) and LC50 of 
etoposide (63 µM) were selected in evaluation 
of apoptosis using flow cytometry. 
 For each experiment of each drugs, 2 well of 
6-wells plates of 5 × 105 HFFF cells were used 
and each experiment was repeated 2 times. 
 
Statistitical analysis 
Descriptive results for quantitative variables 
were expressed as mean±SD. Analysis of data 
was performed using the Student's t-test or x2 
test. Mean difference between groups was 
calculated by one and two-way analysis of 




The effects of etoposide and human 
calprotectin on the HFFF cell proliferation 
    The results of cytotoxicity effect of 
etoposide and calprotectin on HFFF cells in 
different concentrations and time intervals (24, 
48 and 72 h) are shown in the Figures 1 and 2 
respectively. The results of Figures 1 and 2 
show that cytotoxic effects of etoposide and 
calprotectin on HFFF cells are dose and 
incubation time dependent. Proliferation 
inhibitory affecting of human calprotectin and 
etoposide were significant with all 
concentrations and all time intervals except for 
1.025 µM at 24 h incubation time (P<0.001 by 
one-way ANOVA). Results are expressed as 
percentage of viability compared to control 
and are presented as mean±SD. Significance 
levels by one way ANOVA are *:  P<0.05; **: 
P < 0.01; ***: P< 0.001 that calculated from 






































Measuring apoptotic cell induction 
 To quantify the frequency of apoptotic cells 
induced by human calprotectin, Annexin-V/PI 
double staining was performed. The cells were 
treated with calprotectin (38 µM) and 
etoposide (63 µM) (positive control) for 18, 36 
and 48 h. Cell surface expression of  
phosphatidylserine (PS) translocated from the 
inner cytoplasmic membrane is considered an 
early apoptotic event. By treating cells with 
either etoposide or calprotectin and then 
analyzing with flow cytometry, four 





































Figure 2. Measuring the inhibitory effect of different 
concentrations of human calprotectin on HFFF cell 
proliferation. 
 
Alive cells are double negative and are seen in 
the lower left quadrant [A3]. Cells that are 
Annexin V-FITC (+)/PI (-) [A4] are apoptotic. 
The Annexin V-FITC (+)/PI (+) cell 
population [A2] has been described as necrotic 
or advanced apoptotic. The last quadrant [A1] 
Annexin V-FITC (-)/PI (+) may be bare 
nuclei, cells in late necrosis, or cellular 
debris.Our data represent that the cytotoxicity 
of both calprotectin and etoposide on the 
HFFF cells occurs through apoptosis.The 
apoptotic index values were determined using 
the flow cytometry results and have been 
shown in Table 1 and representative Figure 3.  
Figure 1. Measuring the inhibitory effect of various 
concentrations of etoposide on HFFF cell proliferation.
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Figure 3. Flow cytometry analysis of the effect of human calprotectin on HFFF cell and compare with etoposide (positive 
control) and normal cell (negative control) after 18, 36 and 48 h incubation (A, B and C, respectively). Viable cells or 
Annexin-FITC (-) /PI (-) [A3] are seen in the lower left quadrant. Cells that are Annexin V-FITC (+)/ PI(-) [A4] are 
apoptotic (lower right). The cell population with Annexin V-FITC (+)/PI (+) [A2] has been described as necrotic or 
advanced apoptotic (upper right) and Annexin V-FITC (-)/ PI (+) [A1] may be bare nuclei, cells in late necrosis, or cellular 
debris (upper left). 
 
Table 1. Apoptotic index (n = 3) of the HFFF cells treated with human calprotectin (38µM) and etoposide (63 µM) for 
different incubation times. Results were expressed as the means ± SD. 
 
Calprotectin  Etoposide Calprotectin  Etoposide Calprotectin  Etoposide Agents   
Cells (%) 18  (h) 36 (h) 48  (h)
Necrotic 13.38±4.50  16.58±3.17 13.68±2.34  37.66±7.64 11.17±2.21  21.86±3.36 
Late apoptotic 22.71±4.13  2.00±0.08 2.76±0.65  4.45±1.07 13.34±3.03  11.81±1.03 
Alive 42.52±3.63   78.40±7.18 65.39±5.54  54.20±7.40 40.93±7.04  45.21±4.73 
Early apoptotic 21.39±2.53  3.02±0.65 18.17±4.65  3.68±1.03 34.55±4.65  21.13±2.34 




    Fibroblasts are derived from primitive 
mesenchyme and synthesize and maintain the 
extracellular matrix of many animal tissues 
(23). Fibroblast as a kind of normal cell with 
high capacity in proliferation plays a central 
role in the support and repair of almost every 
tissue and organ, and the adaptability of their 
differentiated character is an important feature 
of the responses to many types of damage. 
Here, Inhibitory effects of calprotectin and 
etoposide on HFFF cell lines were compared. 
Etoposide is an important chemotherapeutic 
agent that is used frequently to treat a wide 
spectrum of human cancers [24-28]. As it is 
shown in the Figure 1, the result of treating 
cultured HFFF with etoposide shows that this 
drug has an inhibitory effect on the fibroblast 
proliferation. Figure2 represents the inhibitory 
effect of calprotectin on the fibroblast 
proliferation.Comparing the effect of 
calprotectin with etoposide indicates that the 
same concentration (16.4 µM) of calprotectin 
and etoposide has a similar effect on the 
fibroblast viability at the 24 h, but calprotectin 
decreases the cell survival at the 72 h, two 
times more than etoposide. So, cytotoxicity 
effect of calprotectin on fibroblast depends on 
time.Therefore, in longer incubation time of 
calprotectin with fibroblast cells has a further 
cytotoxic effect than etoposide. A perevious 
study demonstrated that calprotectin compare 
to etoposide has more potent cytotoxicity 
effect on cancer cells [29]. The 50% LC50 
values of human calprotectin and etoposide on 
HFFF cells at 48 h are 38 and 63 µM 
respectively.  
The mechanism of cell apoptosis stimulated 
by calprotectin has not been fully elucidated. 
It has been reported that calprotectin may 
induce apoptosis of multiple tumor cells and 
consequent inhibition of carcinogenesis by 
inhibition of casein kinase I and II that inhibit 
phosphorylation of topo II [30] and activating 
caspases [31]. Previous studies demonstrated 
that calprotectin inhibits the activity of casein 
kinase II, which is involved in the 
phosphorylation of several enzymes including 
topo I and II [32]. Because the inhibitors of 
topo activity induce cell death through 
apoptosis in various cells [33], it is possible 
that cell death inducing activity of calprotectin 
is governed somehow by regulation of topo 
activity in target cells. The ability to 
simultaneously measure multiple parameters 
on a cell by cell basis is probably the most 
powerful aspect of analytical flow cytometry. 
This allows flow cytometry to be used for a 
wide range of applications. Perhaps the most 
common use is the identification of the 
presence of antigens either on the surface of or 
within cells [34]. As it is depicted in Figure 3, 
cells divided to 4 types of alive, necrotic, early 
apoptotic and late apoptotic groups. In normal 
cells, PS residues are found in the inner 
membrane of the cytoplasmic membrane. 
During apoptosis, the PS residues are 
translocated in the membrane and are 
externalized. In general, though not always, 
this is an early event in apoptosis and is 
thought to be a signal to neighboring cells that 
a cell is ready to be phagocytosed. Annexin-V 
is a specific PS-binding protein that can be 
used to detect apoptotic cells [35]. Treatment 
of the HFFF cells with human calprotectin and 
etoposide for all times demonstrated that 
calprotectin caused HFFF cell dead through 
apoptosis and there are no significant 
difference in apoptosis induction by etoposide 
and human calprotectin on HFFF cell line. 
Other investigators previously determined the 
apoptotic inducing activity on other kinds of 
cells (cancer cells) through flowcytometry. 
Mikami et al. [36] by using flow cytometry 
showed that calprotectin, induces apoptotic 
cell death in various tumor cells, suggesting 
that calprotectin is an effector molecule 
against tumor cells in polymorphonuclear 
leukocytes. To explore the cell death-inducing 
mechanism of the factor, Mikami et al. [36] 
and Yui et al. [37] confirmed the involvement 
of target protein synthesis, generation of 
reactive oxygen species and loss of DNA 
content in the reaction. Ghavami et al. by 
using annexin V-fluorescein isothiocyanate 
apoptosis detection kit showed the treatment 
of the colon carcinoma cells with different 
concentrations of human S100A8/A9 induces 
a significant increase in cell death. Annexin 
V/phosphatidylinositol and Hoechst 33258 
staining revealed that the cell death was 
mainly of the apoptotic type [31].  
    The results revealed that calprotectin and 
etoposide induces growth inhibition of HFFF 
in a dose- and time-dependent manner. 
Sensitivity of HFFF cells to cytotoxic effect of 
human calprotectin was highly remarkable. In 
addition, growth inhibitory effect of this 
cytotoxic agent was mostly governed through 
induction of apoptosis in the HFFF cells. 
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Taken together, calprotectin has not only more 
potent anticancer activity in comparison to the 
etoposide but it also is as apoptosis inducer 
that acts on the proliferation of normal cell 
like fibroblast.  
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